Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.

Abstract:

:This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21, cisplatin 100 mg/m2 i.v. on day 2 and VP-16 100 mg/m2 i.v. on day 2-4, repeated every 3 weeks. Eighteen patients were evaluable for toxicity and response. The doses of Ro 40-8757 ranged from 84 mg/m2 once daily to 42 mg/m2 thrice daily (tid). DLT consisting of delayed nausea/vomiting was reached at 42 mg/m2 tid. Consequently, the maximum tolerated dose was set at one dose level below the DLT, i.e. 28 mg/m2 tid. Skin toxicity occurred but was well manageable. Pharmacological analyses showed a small increase in the volume of distribution of cisplatin and VP-16 between the first and third course. However, no relationship with side effects was found. A response was achieved in 50% of patients. The combination of cisplatin/VP-16 with Ro 40-8757 appears to be feasible at a dose schedule of 28 mg/m2 tid. The response rate was at the upper rate of what can be expected with cisplatin and VP-16.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

doi

10.1097/00001813-199904000-00003

subject

Has Abstract

pub_date

1999-04-01 00:00:00

pages

361-8

issue

4

eissn

0959-4973

issn

1473-5741

journal_volume

10

pub_type

临床试验,杂志文章
  • Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

    abstract::There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to indivi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000628

    authors: Franken MG,Leeneman B,Jochems A,Schouwenburg MG,Aarts MJB,van Akkooi ACJ,van den Berkmortel FWPJ,van den Eertwegh AJM,de Groot JWB,van der Hoeven KJM,Hospers GAP,Kapiteijn E,Koornstra R,Kruit WHJ,Louwman MWJ,Piersma D,van

    更新日期:2018-07-01 00:00:00

  • Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice.

    abstract::The in vitro antitumor activity of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, was compared with that of adriamycin (ADM) against human breast carcinomas inoculated into nude mice at the maximum tolerated dose (MTD) and clinically equivalent dose (CED). The plasma levels of NVB after intravenous inje...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199412000-00004

    authors: Tsuruo T,Inaba M,Tashiro T,Yamori T,Ohnishi Y,Ashizawa T,Sakai T,Kobayashi S,Gomi K

    更新日期:1994-12-01 00:00:00

  • Asbestos-related benign disease and cancer: symptoms and treatment.

    abstract::Long lasting occupational exposure to asbestos dust may cause skin corns, benign pleural effusion, hyaline plaques of the parietal pleura, diffuse thickening of the pulmonary pleura, and asbestosis, i.e. diffuse interstitial pulmonary fibrosis. Malignant disorders include lung cancer and mesothelioma of the pleura, pe...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199012000-00012

    authors: Gruber UF

    更新日期:1990-12-01 00:00:00

  • Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Stud

    abstract::A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3282fb178a

    authors: Hejna M,Raderer M,Zacherl J,Ba-Ssalamah A,Püspök A,Schmidinger M,Pluschnig U,Brodowicz T,Zielinski CC

    更新日期:2008-06-01 00:00:00

  • In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by novel traditional Chinese medicine-platinum anti-cancer agents.

    abstract::Protein phosphatase 2A (PP2A) is a new target for platinum (Pt)-based cancer chemotherapeutic agents. A series of novel Pt complexes containing demethylcantharidin, a modified component of a traditional Chinese medicine (TCM), [Pt(C8H8O5)(NH2R)2] 1-5 have been shown to inhibit PP2A both in its purified form and in cel...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000175586.31940.50

    authors: To KK,Ho YP,Au-Yeung SC

    更新日期:2005-09-01 00:00:00

  • Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.

    abstract::The efficacy of chemotherapy for advanced gastric cancer with palliative intent compared with supportive care alone is now widely accepted. However, the best choice of chemotherapy regimen for patients with advanced gastric cancer is still a matter of controversy and requires further investigation. This study is perfo...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283273509

    authors: Cao W,Yang W,Lou G,Jiang J,Geng M,Xi W,Li H,Ma T,Jin Y

    更新日期:2009-04-01 00:00:00

  • An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.

    abstract::The array of tools currently available and the aim of treatment make choosing the best therapeutic strategy in metastatic colorectal cancer (CRC) an increasing challenge worldwide. We present the case of a 53-year-old man with metachronous metastases (liver-only metastatic disease) treated with FOLFOXIRI as first-line...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000761

    authors: Rizzo A,Palloni A,Frega G,Abbati F,De Lorenzo S,Brocchi S,Brandi G

    更新日期:2019-04-01 00:00:00

  • A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.

    abstract::9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199801000-00004

    authors: Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

    更新日期:1998-01-01 00:00:00

  • Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.

    abstract::The aim of the study was to characterize the relationship between the pharmacokinetics of methotrexate in serum and concentrations in the cerebrospinal fluid, and to analyse the association to risk of a central nervous system relapse in children with acute lymphoblastic leukaemia. In this retrospective study, 353 chil...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3281430bd1

    authors: Jönsson P,Höglund P,Wiebe T,Schrøder H,Seidel H,Skärby T

    更新日期:2007-09-01 00:00:00

  • Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.

    abstract::The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer. Secondary objectives included evaluation of the safety and efficacy of the regimen. Patients (n=19) with ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-200501000-00003

    authors: Schmid P,Krocker J,Schulz CO,Michniewicz K,Dieing A,Eggemann H,Heilmann V,Blohmer JU,Sezer O,Elling D,Possinger K

    更新日期:2005-01-01 00:00:00

  • Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.

    abstract::The combination of platinum and paclitaxel is the standard treatment of advanced ovarian carcinoma; however, recent studies have questioned the actual role of the combination as compared to either of the two agents alone. We report an open-label, two-center, phase II study of upfront paclitaxel for patients with histo...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200306000-00004

    authors: Gallardo-Rincón D,Pérez-Landeros L,Oñate-Ocaña LF,Mohar A,Calderillo G,de la Garza J,Cabrera P,Sánchez B,Dueñas-Gonzalez A

    更新日期:2003-06-01 00:00:00

  • Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro.

    abstract::Glucosinolates hydrolysis products are attracting increasing attention since many studies have suggested that they may be involved in the anticarcinogenic property of cruciferous vegetables. In this study, we show that diindolylmethane (DIM) and sulforaphane, produced during the hydrolysis of glucobrassicin and glucor...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199802000-00005

    authors: Gamet-Payrastre L,Lumeau S,Gasc N,Cassar G,Rollin P,Tulliez J

    更新日期:1998-02-01 00:00:00

  • Alpha-tocopherol ameliorates cyclophosphamide-induced hyperlipidemia in fibrosarcoma-bearing rats.

    abstract::Cyclophosphamide, an alkylating agent, is currently being used for the treatment of various types of cancer, either alone or in combination with other cytostatic drugs. However, cyclophosphamide has a detrimental effect on lipid metabolism and causes hyperlipidemia in patients. Since alpha-tocopherol is known to reduc...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199512000-00009

    authors: Ilanchezhian S,Thangaraju M,Sasirekha S,Sachdanandam P

    更新日期:1995-12-01 00:00:00

  • Determination of the maximal carcinoma/normal skin ratio after HpD or m-THPC administration in Hairless mice (SKH-1) by fluorescence spectroscopy.

    abstract::The two major steps in our study on the treatment of skin carcinomas by photochemotherapy (PCT) were the development of a skin tumor model in Hairless mice by a chemical carcinogenesis and the use of fluorescence spectroscopy, a semi-quantitative and non-invasive method, in order to determine the time after i.p. injec...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200002000-00004

    authors: Bossu E,Padilla-Ybarra JJ,Notter D,Vigneron C,Guillemin F

    更新日期:2000-02-01 00:00:00

  • Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.

    abstract::We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer. Medical care consumption data were collected prospective...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00001813-199907000-00014

    authors: Schmitt C,Blijham G,Jolain B,Rougier P,Van Cutsem E

    更新日期:1999-07-01 00:00:00

  • Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-deoxy-Delta7 -prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826).

    abstract::13,14-Dihydro-15-deoxy-Delta7-prostaglandin A1 methyl ester (TEI-9826), an antitumor prostaglandin analog, is a candidate for clinical trial. In the present study, we examined its biological stability in vitro, antitumor activity in vitro and in vivo, and pharmacokinetics. Although TEI-9826 was rapidly hydrolyzed to t...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200103000-00008

    authors: Fukushima S,Takeuchi Y,Kishimoto S,Yamashita S,Uetsuki K,Shirakawa S,Suzuki M,Furuta K,Noyori R,Sasaki H,Kikuchi Y,Kita T,Yamori T,Sawada J,Kojima M,Hazato A,Kurozumi S,Fukushima M

    更新日期:2001-03-01 00:00:00

  • Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.

    abstract::Results are summarized for two phase II studies of docetaxel as first-line therapy for advanced squamous cell carcinoma of the head and neck (SCCHN) and one study of docetaxel as second-line therapy for advanced soft tissue sarcomas. In all three studies, docetaxel was administered at a dose of 100 mg/m2 by intravenou...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199507004-00004

    authors: Verweij J

    更新日期:1995-07-01 00:00:00

  • The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.

    abstract::Adrenocortical tumor (ACT) is a malignancy with a low incidence rate and the current therapy for advanced disease has a limited impact on overall patient survival. A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT. Similar resul...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000504

    authors: Borges KS,Andrade AF,Silveira VS,Marco Antonio DS,Vasconcelos EJR,Antonini SRR,Tone LG,Scrideli CA

    更新日期:2017-07-01 00:00:00

  • Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.

    abstract::Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000592

    authors: Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

    更新日期:2018-04-01 00:00:00

  • Selective delivery of etoposide to intraperitoneal tissues using a new dosage format: etoposide microcrystals suspended in oil.

    abstract::Rats received an intraperitoneal bolus injection of etoposide at 5 mg/kg of body weight in the form of an etoposide microcrystal suspension in oil (ETOP-OIL) or an aqueous etoposide solution. The tissue distribution was subsequently analyzed using high performance liquid chromatography. ETOP-OIL delivered significantl...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199302000-00003

    authors: Hagiwara A,Takahashi T,Lee M,Sakakura C,Shoubayashi S,Tashima S,Yamamoto A,Muranishi S

    更新日期:1993-02-01 00:00:00

  • Endometrial stromal sarcoma of the uterus.

    abstract::Uterine sarcomas are rare tumors constituting 1-3% of all uterine malignancies. These tumors are characterized by aggressive growth and by poor overall prognosis. There is much controversy concerning diagnostic criteria and the great variation in histology, as well as the role of radiotherapy and chemotherapy in the m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199102000-00004

    authors: Meden H,Meyer-Rath D,Schauer A,Kuhn W

    更新日期:1991-02-01 00:00:00

  • Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

    abstract::Gastrointestinal stromal tumors (GIST) are the most common malignant mesenchymal tumors of the gastrointestinal tract. The principal treatment modality for primary GIST is surgery whereas for metastatic GIST, imatinib has an established role. In patients with locally advanced and metastatic GIST, the role of surgery i...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32830138f9

    authors: Mearadji A,den Bakker MA,van Geel AN,Eggermont AM,Sleijfer S,Verweij J,de Wilt JH,Verhoef C

    更新日期:2008-07-01 00:00:00

  • Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.

    abstract::Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors. It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations. Imatinib-associated adverse events are generally mild to moderate; how...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000331

    authors: Saponara M,Gatto L,Di Nunno V,Tabacchi E,Fanti S,Di Scioscio V,Nannini M,Gruppioni E,Altimari A,Fiorentino M,Santini D,Ceccarelli C,Zompatori M,Biasco G,Pantaleo MA

    更新日期:2016-04-01 00:00:00

  • 7-Keto hybrid steroidal esters of nitrogen mustard: cytogenetic and antineoplastic effects.

    abstract::Four newly synthesized antitumor steroidal compounds were compared, on a molar basis, regarding their ability to induce sister chromatid exchanges (SCEs) and cell division delays. The concept of designing and developing these compounds (1-4) is to enhance the anticancer activity of esteric steroidal derivatives of nit...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200207000-00011

    authors: Karayianni V,Papageorgiou A,Mioglou E,Iakovidou Z,Mourelatos D,Fousteris M,Koutsourea A,Arsenou E,Nikolaropoulos S

    更新日期:2002-07-01 00:00:00

  • Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.

    abstract::The effects of 1-(biphenyl-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol (EDL-155) on the growth of glioma was tested in vitro and in vivo. Normal cultured rat astrocytes and C6 rat glioma were used as a differential screen to test the effects of EDL-155. The compound was preferentially cytotoxic for C6 glioma (...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32830d5887

    authors: Kang GS,Wang XD,Mohler ML,Kirichenko OV,Patil R,Orr WE,Miller DD,Geisert EE

    更新日期:2008-10-01 00:00:00

  • Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.

    abstract::Small molecule tyrosine kinase inhibitors are rapidly being integrated into the management of cancer. This is the first report of sorafenib and sunitinib, both small molecule tyrosine kinase inhibitors of vascular endothelial growth factor and platelet-derived growth factor receptors, triggering radiation recall derma...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328333d679

    authors: Chung C,Dawson LA,Joshua AM,Brade AM

    更新日期:2010-02-01 00:00:00

  • Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma.

    abstract::Metastatic meningioma is a rare disease, which has no effective chemotherapy. We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation. A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months w...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200303000-00009

    authors: Travitzky M,Libson E,Nemirovsky I,Hadas I,Gabizon A

    更新日期:2003-03-01 00:00:00

  • Para-toluenesulfonamide induces tongue squamous cell carcinoma cell death through disturbing lysosomal stability.

    abstract::Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liq...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000283

    authors: Liu Z,Liang C,Zhang Z,Pan J,Xia H,Zhong N,Li L

    更新日期:2015-11-01 00:00:00

  • Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.

    abstract::We carried out a detailed comparative study of the pharmacokinetics and toxicity of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) after high-dose intravenous methotrexate (HD-MTX) in children with acute lymphoblastic leukemia (ALL). Overall, 65 children were treated with 5 g/m2/24 h MTX and 88 children were...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/CAD.0b013e32835b8662

    authors: Csordas K,Hegyi M,Eipel OT,Muller J,Erdelyi DJ,Kovacs GT

    更新日期:2013-02-01 00:00:00

  • Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.

    abstract::Our objective was to determine the maximum tolerated dose (MTD) of paclitaxel when given as a 7 day continuous i.v. infusion, repeated every 3 weeks, and to evaluate the toxicity and the efficacy of such a schedule of administration as a salvage treatment in ovarian cancer patients pretreated and refractory to 3 or 24...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199709000-00005

    authors: Soulié P,Trandafir L,Taamma A,Lokiec F,Brain E,Delord JP,Mita A,Vannetzel JM,Cvitkovic E,Misset JL

    更新日期:1997-09-01 00:00:00